TY  - JOUR
AU  - Liebers, Nora
AU  - Bruch, Peter-Martin
AU  - Terzer, Tobias
AU  - Hernandez-Hernandez, Miguel
AU  - Paramasivam, Nagarajan
AU  - Fitzgerald, Donnacha
AU  - Altmann, Heidi
AU  - Roider, Tobias
AU  - Kolb, Carolin
AU  - Knoll, Mareike
AU  - Lenze, Angela
AU  - Platzbecker, Uwe
AU  - Röllig, Christoph
AU  - Baldus, Claudia
AU  - Serve, Hubert
AU  - Bornhäuser, Martin
AU  - Hübschmann, Daniel
AU  - Müller-Tidow, Carsten
AU  - Stölzel, Friedrich
AU  - Huber, Wolfgang
AU  - Benner, Axel
AU  - Zenz, Thorsten
AU  - Lu, Junyan
AU  - Dietrich, Sascha
TI  - Ex vivo drug response profiling for response and outcome prediction in hematologic malignancies: the prospective non-interventional SMARTrial.
JO  - Nature cancer
VL  - 4
IS  - 12
SN  - 2662-1347
CY  - London
PB  - Nature Research
M1  - DKFZ-2023-01992
SP  - 1648-1659
PY  - 2023
N1  - 2023 Dec;4(12):1648-1659 / #EA:B340#LA:B340#
AB  - Ex vivo drug response profiling is a powerful tool to study genotype-drug response associations and is being explored as a tool set for precision medicine in cancer. Here we conducted a prospective non-interventional trial to investigate feasibility of ex vivo drug response profiling for treatment guidance in hematologic malignancies (SMARTrial, NCT03488641 ). The primary endpoint to provide drug response profiling reports within 7 d was met in 91
LB  - PUB:(DE-HGF)16
C6  - pmid:37783805
DO  - DOI:10.1038/s43018-023-00645-5
UR  - https://inrepo02.dkfz.de/record/284403
ER  -